8. Medication Treatment in Multiple Sclerosis

  1. Howard L. Weiner MD2,3,4 and
  2. James M. Stankiewicz MD2,3
  1. James M. Stankiewicz MD2,3 and
  2. Samia J. Khoury MD, FAAN1,3

Published Online: 23 FEB 2012

DOI: 10.1002/9781119963714.ch8

Multiple Sclerosis: Diagnosis and Therapy

Multiple Sclerosis: Diagnosis and Therapy

How to Cite

Stankiewicz, J. M. and Khoury, S. J. (2012) Medication Treatment in Multiple Sclerosis, in Multiple Sclerosis: Diagnosis and Therapy (eds H. L. Weiner and J. M. Stankiewicz), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119963714.ch8

Editor Information

  1. 2

    Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA

  2. 3

    Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA

  3. 4

    Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA

Author Information

  1. 1

    Department of Neurology, Harvard Medical School, Boston, MA, USA

  2. 2

    Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA

  3. 3

    Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA

Publication History

  1. Published Online: 23 FEB 2012
  2. Published Print: 6 APR 2012

ISBN Information

Print ISBN: 9780470654637

Online ISBN: 9781119963714

SEARCH

Keywords:

  • Avonex (IFN-beta-1a);
  • Betaseron (IFN-beta-1b);
  • Rebif (IFN-beta-1a);
  • Copaxone (glatiramer acetate);
  • Tysabri (natalizumab);
  • Cytoxan (cyclophosphamide);
  • Cellcept (mycophenolate mofetil);
  • Rituxan (rituximab);
  • Gilenya (fingolimod);
  • treatment;
  • steroids;
  • plasmapheresis;
  • IVIg;
  • Immuran (azathioprine);
  • methotrexate;
  • Novantrone (mitoxantrone)

Summary

Treatment of multiple sclerosis continues to evolve. New understandings occur about old drugs and new drugs are released. In this chapter we provide an overview of treatment in MS. We review the long-standing FDA approved therapies including the injectables and Tysabri. We then turn toward medications approved but used off label including commonly used immunosuppressives such as cyclophophamide, mycophenolate mofetil, and steroids. We discuss the newly approved oral medication fingolimod at length. We also discuss therapies in phase III trial that may soon gain approval. Where possible we try to indicate how we employ these drugs clinically.